Sign in with Google
bullish
Hanmi Pharm (128940 KS): Core Products Continue to Drive Sales; Pipeline Progress Raises Hope
349 Views03 Oct 2023 15:50
SUMMARY
- With 1H23 revenue of KRW704 billion, Hanmi Pharm (128940 KS) is on track on surpass its 2022 revenue of KRW1.33 trillion to reach a new high in 2023.
- Hanmi is developing epeglenatide as personalized obesity drug for South Korean market. With the spectacular success of obesity drugs in the U.S., epeglenatide seems to be have great market potential.
- Outlicensing partner Merck is conducting phase 2b trial on efinopegdutide for NASH, with result expected in 2025. Efinopegdutide obtained fast track designation from FDA, which should accelerate its commercialization.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Smartkarma Corporate Webinar | MoneyHero Group: Driving Expansion and Innovation in Greater Southeast Asia
- Rio Tinto (RIO AU/RIO LN): Unification Index Flows
- [Activism Japan] Nissan Tokyo Sales (8291) Gets An 'Outsourced Activist' but the Value Prop Remains
- Recruit Holdings Placement - Relatively Small US$520m Deal but Momentum Is Weak
- Asian Equities: Valuation Mean Reversion - The Winners and Losers
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Hanmi Pharm (128940 KS): Corporate Value Enhancement Plan Targets W5 Trillion Revenue by 203310 Mar 2025
- OCI Or No OCI, Hanmi Pharm (128940 KS) Will Continue to Roar on Strong Base Business and Pipeline14 Mar 2024
- Hanmi Pharm (128940 KS): Core Products Continue to Drive Sales; Pipeline Progress Raises Hope03 Oct 2023
- Hanmi Pharm (128940 KS): Strong Base Business; Innovative Biologic Drug Commercialized in US26 Mar 2023
x